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888-4 Changes in Plasma Brain Natriuretic Peptide and 
Norepinephrine Over Time and Subsequent Mortality 
and Morbidity in Heart Failure: Results From Val-HeFT 
lnderiit S. Anand, Lloyd Fisher, Yam-Tom Chiang, Roberto Latini. Serge Masson, Aldo 
Maggioni, Robert Glazer. Gianni Tognoni, Jay N. Cohn, for the Val-HeFT Investigators, 
VA Medical Center and University of Minnesota, Minneapolis, MN, University of 
Washington, Seattle, WA 
Background: Plasma brain natriuretlc peptide (BNP) and norepinephrine (NE) are impor- 
tant predictors of heart failure (HF) morlallty and morbidity (M&M). Whether changes in 
BNP and NE over time correspond to subsequent changes in M&M has not been studied. 
Val-HeFT evaluated the efficacy of valsartan in HF patients and measured BNP and NE 
at baseline (BL) and during follow-up. Methods: BL and % change from BL to 4 months in 
BNP (n=3740) and NE (n=3746) were analysed by quartiles (0) for subsequent mortality 
and morbidity (death, sudden death with resuscitation. IV inotropic therapy, and hospital- 
isation for HF), usmg a Cox proportional hazard model with BL value as a covariate. The 
hazard risk ratio (RR) and 95% Cl for changes between Q, using first Q as control was 
calculated for mortality and first motiid event in all patients. irrespecttve of treatment. 
Results: BL BNP and NE showed a significant quartile-dependent increase in M&M. 
Patients with the greatest % decrease in BNP and NE from baseline to 4 months (Ql) 
had the lowest, whereas patients with greatest % increase in BNP and NE had the high- 
est subsequent M&M. (Table). Findings were similar for NE but RR were lower than for 
BNP. Conclusions: Plasma BNP and NE are not only important predictors of HF M&M, 
but changes m these neurohormones over time are associated with corresponding 
changes in subsequent M&M. These data further reinforce their role as significant surro- 
gate markers in HF and underscore the importance of Including their measurement in HF 
clinical trials. 
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888-5 B-Type Natriuretic Peptide and Renal Function in the 
Diagnosis of Heart Failure: An Analysis From the BNP 
Multinational Study 
Peter A. McCullouoh Philippe Due, Torbjorn Omland, James McCord. Richard M. 
Nowak. Judd E. Hollander. Howard C. Herrmann. Philiooe Gabriel S&a. Ame Westheim. ., 
Marie-Claude Aumont, Catherine W. Knudsen, Alan B. Storrow, William T. Abraham, 
Sumant Lamba, Alan H. Wu, Alberta Perez, Paul Clopton, Padma Krishnaswamy, 
Radmila Kazanegra, Alan S. Maisel, BNP Multinational Study Investigators. William 
Beaumont Hospital, Royal Oak, MI, University of California, San Diego School of 
Medicine, Veterans Affairs Medical Center, San Diego, CA 
Background B-type natriuretic peptide (BNP) and renal function are prognostic indica- 
tors of suwival in patients with congestive heart failure (CHF). We sought to define the 
relationships between BNP and renal function. 
Methods and Results-The Breathing Not Properly Multinational Study was a prospec- 
tively designed, diagnostic test evaluation study conducted in seven centers. Of 1566 
participants who presented with acute dyspnea, 1452 (91.6%) had both BNP and base- 
line estimated glomerular filtration rate (eGFR) available. Patients with eGFR < 15 ml/ 
mini 1.73 m2 and those on dialysis were excluded. The final diagnosis was CHF in 715 
(49.2%). The raw, and log-log transformed correlations between BNP and eGFR were r = 
- 0.19 and r = -0.17, and I = - 0.20 and r = - 0.31, for those with and without CHF, both p 
< 0.0001 for I d 0. There were graded increases in BNP for those with and without CHF 
with decreasing renal function (Figure). The following variables, in ranked order, were 
found to be most independently predictive of CHF as a final diagnosis: 1) log (BNP), OR 
= 13.5, 95% Cl 10.1-16.4. p < 0.0001; 2) history of CHF, OR 5.0, 95% Cl 3.6-7.0. p < 
0.0001; 3) S,, OR = 6.0, 95% Cl 2.8-12.7. p < 0.0001; 4) diabetes, OR = 1.6, 95% Cl 1.1. 
2.3, p=O.O1;5) log(eGFR),OR0.5, 95%CI 0.2-1.0, p=O.O7. 
JACC March 19,2003 
Conclusions With decreasing eGFR, there are graded increases I” BNP among those 
with and without CHF. Despite a weak correlation between BNP and eGFR, BNP is a 
strong and independent predictor of CHF after taking renal function into consideration. 
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888-6 What Is the Normal Range for N-Terminal Pro-Brain 
Natriuretic Peptide Levels in the Community? 
Gavin I. Galasko, Sophie Barnes, David Gaze, Paul Collinson, Roxy Senior. Avijit Lahiri, 
Northwick Park Hospital, London, Unlted Kingdom, St. George’s Hospital, London, 
United Kingdom 
Background: Heart failure (HF) is placing an increasing burden on society. Data sug- 
gests that N-terminal pro-Brain Natriuretic Peptide (NTB) is secreted from the ventricles 
of subjects with HF and that its serum concentration may help diagnose HF. Serum NTB 
levels can now be measured by autoanalyset in the laboratory. Little data has been col- 
lected on normal ?&rum NTB values and differences with age and gender in healthy sub- 
jects in the community. 
Methods: Accordingly, 1403 subjects 2 45 years old were chosen at random from 7 rep- 
resentative local general practices and invited to attend for echocardiography, venesec- 
tion for serum NTB levels (Elecys, Roche Diagnostics) and a questionnaire. Subjects 
were classified as normal if they had no prior ischaemic heart disease, diabetes. cete- 
brovascular disease, peripheral vascular disease or hypeltension; were normotensive, 
and had normal systolic and diastolic function, normal valves and no left ventricular 
hypertrophy on echocardiography. 
Results: 734 subjects (52%) attended. 290 subjects (40%) were classified as normal. 
Serum NTB levels in normal subjects are shown below. NTB levels increased with age 
(p<O.OOl age 45-54 vs 65+, p=O.O03 age 55-64 vs 65+). NTB levels were higher in 
females than males at each age cut off (p<O.OOl age 45-54, pcO.001 age 55-64. p=O.O3 
age 65+). 
Conclusion: Thus in normal healthy subjects serum NTB levels increase with age and 
female gender, requiring age and gender specific cutoffs to be used when ising NTB in 
clinical practice. 
Serum NTB levels (pg/ml) stratified for age and gender 
Males Females Males Females Males Females 
Age 45. Age 45. Age 55. Age 55. Age Age 
54 54 64 64 65+ 
Median NTB 19.5 46 17 61 42 
levels (pg/ml) 
Mean NTB 25.9 60.6 24.1 78.6 62.4 
levels (pgfml) 
Mean +2SD 75.8 152 71.2 166 157 
NTB levels (pg/ 
ml) 
97.5th Gentile 96.6 183 243 - 
NTB levels (pgi 
ml) 
Number 76 90 37 45 20 
subjects 
65+ 
83.5 
Ill 
265 
22 
